1
|
Mezaache S, Turlure F, Fredon N, Le Brun Gadelius M, Micallef J, Frauger E. [Opioid overdose prevention and naloxone diffusion (POP program): Results of an overview conducted among addiction specialized centres]. Therapie 2023; 78:605-614. [PMID: 37012152 DOI: 10.1016/j.therap.2023.03.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2022] [Revised: 02/20/2023] [Accepted: 03/13/2023] [Indexed: 03/17/2023]
Abstract
INTRODUCTION In France, opioids are responsible for the majority of overdose deaths in France. The antidote naloxone is available in France in take home formulations since 2016. Addiction specialized centres are in front-line for naloxone diffusion. The objective was to provide an overview of professional practices, difficulties and needs regarding overdose prevention and naloxone diffusion in these centres of the Provence-Alpes-Côte d'Azur (PACA) region. METHODS The POP programme "Prevention and harm reduction of opioid overdoses in PACA region" aims to improve the care of patients at risk of overdose and facilitate naloxone diffusion. The 75 addiction specialized centres of the PACA region were invited to respond to a semi-structured interview or a telephone questionnaire. Data collected included 2020 centres' activity and professionals' perceptions of overdose risk in their active file, their practices, difficulties and needs. RESULTS Overall, 33 centres answered. Among them, 22 were dispensing naloxone with a mean of 20 kits dispensed in 2020 (min-max: 1-100). Two strategies were pointed out: systematically offering of naloxone to all opioids users or targeting people considered at risk. Several difficulties limiting naloxone diffusion were expressed: a lack of knowledge from opioids users, refusal from people not feeling concerned or refusing the injectable formulation, a lack of training of some professionals to be comfortable with the tool or reglementary or time constraints. CONCLUSION Naloxone diffusion is incrementally getting into common practices. However barriers are persisting. On the basis of expressed difficulties and needs, information and training materials were co-designed and diffused.
Collapse
Affiliation(s)
- Salim Mezaache
- Centre d'évaluation et d'information sur la pharmacodépendance-addictovigilance (CEIP-A) PACA Corse, service de pharmacologie clinique et pharmacovigilance, AP-HM-Timone, AMU, INS, Inserm UMR1106, 13000 Marseille, France.
| | - Franck Turlure
- Centre d'évaluation et d'information sur la pharmacodépendance-addictovigilance (CEIP-A) PACA Corse, service de pharmacologie clinique et pharmacovigilance, AP-HM-Timone, AMU, INS, Inserm UMR1106, 13000 Marseille, France
| | - Nathalie Fredon
- Centre d'évaluation et d'information sur la pharmacodépendance-addictovigilance (CEIP-A) PACA Corse, service de pharmacologie clinique et pharmacovigilance, AP-HM-Timone, AMU, INS, Inserm UMR1106, 13000 Marseille, France
| | | | - Joëlle Micallef
- Centre d'évaluation et d'information sur la pharmacodépendance-addictovigilance (CEIP-A) PACA Corse, service de pharmacologie clinique et pharmacovigilance, AP-HM-Timone, AMU, INS, Inserm UMR1106, 13000 Marseille, France
| | - Elisabeth Frauger
- Centre d'évaluation et d'information sur la pharmacodépendance-addictovigilance (CEIP-A) PACA Corse, service de pharmacologie clinique et pharmacovigilance, AP-HM-Timone, AMU, INS, Inserm UMR1106, 13000 Marseille, France
| |
Collapse
|
2
|
Vorspan F, Hjelmström P, Simon N, Benyamina A, Dervaux A, Brousse G, Jamain T, Kosim M, Rolland B. What place for prolonged-release buprenorphine depot-formulation Buvidal® in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine. Expert Opin Drug Deliv 2019; 16:907-914. [PMID: 31364884 DOI: 10.1080/17425247.2019.1649252] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Introduction: Since the 1990s, opioid maintenance treatments (OMTs), i.e. mostly methadone and buprenorphine, have represented the therapeutic cornerstone of opioid dependence. In France, the public health strategy on opioid dependence, identified here as the 'French model', has consisted of offering a facilitated access to buprenorphine, to reach a large treatment coverage and reduce opioid-related mortality. Areas covered: Recently, a new formulation of subcutaneous buprenorphine depot (Buvidal®) has been approved in Europe for treatment of opioid dependence. The place of Buvidal® among the pre-existing arsenal of OMTs is discussed in the light of the pharmacological specificities of this new formulation, and with the particular standpoint of the French model on opioid dependence. Expert opinion: Buvidal® could constitute a promising treatment option mainly in case of: 1) OMT initiation, including in non-specialized addiction medicine care; 2) Discharge from prison or hospital; Diversion/misuse of 3) buprenorphine or 4) methadone; 5) Clinically stabilized patients wishing to avoid daily oral taking of the medication. As such, this new formulation should be highly accessible, which will require specific pathways through care as the product is intended to be administered by a healthcare professional.
Collapse
Affiliation(s)
- Florence Vorspan
- Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, Assistance Publique - Hôpitaux de Paris , Paris , France.,Faculté de Médecine, Université Paris Diderot et INSERM UMRS 1144, Université Paris Descartes, Université Paris Diderot , Paris , France
| | | | - Nicolas Simon
- INSERM, IRD, SESSTIM, Hop Sainte Marguerite, Service de Pharmacologie Clinique, CAP, Aix Marseille Univ , Marseille , France
| | - Amine Benyamina
- CESP, centre d'enseignement, de recherche et de traitement des addictions, université Paris Sud , Villejuif , France
| | - Alain Dervaux
- Service de Psychiatrie et Addictologie de liaison, CHU Sud , Amiens Cedex , France.,Groupe de Recherche sur l'Alcool & les Pharmacodépendances (GRAP) INSERM U1247 , Amiens , France
| | - Georges Brousse
- EA NPsy-Sydo, université Clermont-Auvergne , Clermont-Ferrand , France
| | | | - Margaux Kosim
- Consultations de médecine-Alcoologie PASS, Groupe Hospitalier Pitié Salpêtrière , Paris , France.,Camurus SAS , Paris , France
| | - Benjamin Rolland
- Service Universitaire d'Addictologie de Lyon (SUAL), CH Le Vinatier , Bron , France.,Université de Lyon, UCBL1, INSERM, INSERM U1028, CNRS UMR 5292, CRNL , Bron , France
| |
Collapse
|
3
|
Lenglard F, Berger-Vergiat A, Ragonnet D, Duvernay N, Lack P, Poulet E, Zoulim F, Chappuy M. [Feedback from two French addiction centers and national survey on the intranasal naloxone (Nalscue ®) in the prevention of opioid overdoses]. Therapie 2019; 74:477-486. [PMID: 30792078 DOI: 10.1016/j.therap.2019.01.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2018] [Revised: 12/18/2018] [Accepted: 01/17/2019] [Indexed: 01/01/2023]
Abstract
OBJECTIVE France has temporarily authorized addictology centers to use a form of intranasal naloxone (Nalscue®) to prevent opioid overdoses. The objectives of this work are to present both the characteristics of the patients included in this device in two hospitals centers and the results of the national survey on addiction center's contribution to this new risk reduction tool. METHODS Patient data are those requested under Nalscue® study (inclusion period July 2016 to January 2018). The survey is an online questionnaire distributed to all addiction centers with an email address. RESULTS Over this period, in the two addiction centers, 370 kits (35% of the national total) were distributed to 330 patients including 312 opioid users. Of these users, 15% report injecting and 85% are poly-consumers. In 14% of the cases, a patient's relative was formed to administrate the Nalscue®. Forty kits (30 given away, 6 lost, 4 administered) were renewed to 35 users. Of the 462 addiction centers contacted, 82 (18%) responded. Among 76 structures specialized in opioid addictions, two did not feel concerned and one had no knowledge of the antidote. Fifty-five structures were formed by the pharmaceutical firm. Nine hundred forty-seven patients (58% of the total) were included by 37 centers. Forty-four centers ordered 2458 kits and dispensed 1116 (including kits given out of study). Thirteen structures reported use of Nalscue®. CONCLUSION The interest of intranasal naloxone is no longer to be demonstrated in a context of opioid overdose, but the preauthorized framework did not allow a major diffusion of the antidote within the population most at risk. Let us hope that the availability in pharmacy can promote its distribution and thus reduce the number of deaths.
Collapse
Affiliation(s)
- Flavy Lenglard
- Institut des sciences pharmaceutiques et biologiques de Lyon, 69008 Lyon, France; Service pharmaceutique, groupement hospitalier Centre, hospices civils de Lyon, 69003 Lyon, France
| | - Aurélie Berger-Vergiat
- Service d'addictologie, centre de soins, d'accompagnement et de prévention en addictologie, groupement hospitalier Centre, hospices civils de Lyon, 69003 Lyon, France
| | - Delphine Ragonnet
- Service d'addictologie, centre de soins, d'accompagnement et de prévention en addictologie, groupement hospitalier Centre, hospices civils de Lyon, 69003 Lyon, France
| | - Nathalie Duvernay
- Centre de soins, d'accompagnement et de prévention en addictologie, groupement hospitalier Nord, hospices civils de Lyon, 69004 Lyon, France
| | - Philippe Lack
- Centre de soins, d'accompagnement et de prévention en addictologie, groupement hospitalier Nord, hospices civils de Lyon, 69004 Lyon, France
| | - Emmanuel Poulet
- Service de psychiatrie, groupement hospitalier Centre, hospices civils de Lyon, 69003 Lyon, France
| | - Fabien Zoulim
- Service d'hépatologie et gastro-entérologie, groupement hospitalier Nord, hospices civils de Lyon, 69004 Lyon, France
| | - Mathieu Chappuy
- Service pharmaceutique, groupement hospitalier Centre, hospices civils de Lyon, 69003 Lyon, France; Service d'addictologie, centre de soins, d'accompagnement et de prévention en addictologie, groupement hospitalier Centre, hospices civils de Lyon, 69003 Lyon, France; Centre de soins, d'accompagnement et de prévention en addictologie, groupement hospitalier Nord, hospices civils de Lyon, 69004 Lyon, France; Service pharmaceutique, groupement hospitalier Nord, hospices civils de Lyon, 69004 Lyon, France.
| |
Collapse
|